Nexalin advances pivotal HALO Clarity insomnia trial toward Q2 2026 enrollment with 160-patient study

Nexalin Technology, Inc.

Entered contract with Lindus Health for pivotal study; direct fees ~$944,820 plus pass-through expenses.
160-patient, triple-blinded, sham-controlled trial targeting moderate-to-severe insomnia.
Enrollment expected to begin Q2 2026; study supports planned De Novo FDA submission.
Published peer-reviewed data showed statistically significant improvements vs sham treatment.
Global sleep tech market estimated at $29.3B in 2025, projected to reach $153.7B by 2035.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Nexalin Technology, Inc. entered into Scope of Work with Lindus Health Limited valued at approximately $944,820 (effective 2026-04-17).

Action: entry
Counterparty: Lindus Health Limited
Value: approximately $944,820
Effective: 2026-04-17

Exact text from the filing

On April 17, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Scope of Work (the “SOW”) with Lindus Health Limited (“Lindus Health”), a clinical research organization based in the United Kingdom.

View on SEC.gov

Browse all material agreements →

Nexalin Technology, Inc. filing history →

Source: SEC EDGAR

accession 0001829126-26-003765

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.